Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CORRECTION: Iterum Therapeutics Q2 Adj. EPS $(0.13) Misses $(0.11) Estimate. Cash And Equivalents Of $13M, Runway Into 2026

Author: Benzinga Newsdesk | August 05, 2025 07:49am
Iterum Therapeutics (NASDAQ:ITRM) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 43.48 percent increase over losses of $(0.23) per share from the same period last year.

Posted In: ITRM


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist